Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same

• US 8,481,065 B2
• Filed: 12/16/2010
• Issued: 07/09/2013
• Est. Priority Date: 12/18/2009
• Status: Active Grant

• Current Assignee: Howmedica Osteonics Corp. (Stryker Corporation)
• Original Assignee: Howmedica Osteonics Corp. (Stryker Corporation)
• Inventors: O'Mahony, Donal, Garigapati, Venkat R., Sun Wai, Adrian, Hess, Brian, Murphy, Matthew E.
• Primary Examiner(s): ARNOLD, ERNST V
• Application Number:
  US12/970,393
• Publication Number:
  US 20110152195A1
• Time in Patent Office: 936 Days
• Field of Search: None
• US Class Current: 424/422
• CPC Class Codes: A61L 24/001 Use of materials characterised by their function or physical properties
• CPC Class Codes: A61L 24/02 containing inorganic materials
• CPC Class Codes: A61L 24/06 obtained by reactions only involving carbon-to-carbon unsaturated bonds A61L24/043, A61L24/046 take precedence
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: A61L 27/12 Phosphorus-containing materials, e.g. apatite
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders

Abstract

The present invention relates to a bone cement precursor system that is presented in the form of two shelf-stable pastes which have been terminally sterilized and are held in separate containers during product transport and storage. When the product is used during surgery, these pastes inject to a site of application through a static mixing device by the action of applied injection force. When the two pastes are mixed, they start to react to each other while injecting out. The resulting composition is highly biocompatible, osteoconductive, injectable, rapid setting and bioresorbable, and is useful in connection with bone repair procedures, for example, in the craniomaxillofacial, trauma and orthopedic areas.

Claims

1. A bone cement precursor system comprising:

a first container containing an acidic aqueous paste comprising monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA), citric acid, water, glycerol, polyvinyl pyrrolidone (PVP) and polyethylene glycol (PEG), and

a second container containing an alkaline non-aqueous paste comprising at least one basic calcium phosphate mineral, at least one paste stabilizing agent, a surfactant and a solvent, wherein said at least one basic calcium phosphate mineral is tetra calcium phosphate (TTCP) having a bimodal mean particle size distribution, wherein the mean particle size of a first set of said TTCP is between about 10 μ

m to about 30 μ

m, and the mean particle size of a second set of the TTCP is between about 25 μ

m to about 60 μ

m.

2. The bone cement precursor system of claim 1, wherein said system is shelf-stable post terminal sterilization.

3. The bone cement of claim 2, wherein said terminal sterilization is gamma irradiation.

4. The bone cement precursor system of claim 1, wherein the mean particle size of said monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA) is between about 1 μ

m to about 90 μ

m.

5. The bone cement precursor system of claim 4, wherein the mean particle size of said monocalcium phosphate monohydrate (MCPM) is about 30 μ

m to about 90 μ

m.

6. The bone cement precursor system of claim 4, wherein the mean particle size of said dicalcium phosphate anhydrous (DCPA) is about 1 μ

m to about 20 μ

m.

7. The bone cement precursor system of claim 1, wherein the amount of said monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA) present in said acidic aqueous paste is between about 5% w/w to about 65% w/w based on the total weight of said acidic aqueous paste.

8. The bone cement precursor system of claim 1, wherein the amount of said polyvinyl pyrrolidone (PVP) and polyethylene glycol (PEG) is 1% w/w and about 10% w/w based on the total weight of said acidic aqueous paste.

9. The bone cement precursor system of claim 1, wherein the amount of said citric acid present in said acidic aqueous paste is between about 5% w/w and about 8% w/w based on the total weight of said acidic aqueous paste.

10. The bone cement precursor system of claim 1, wherein the amount of said glycerol present in said acidic aqueous paste is between about 0.5% w/w and about 2% w/w based on the total weight of said acidic aqueous paste.

11. The bone cement precursor system of claim 1, wherein the amount of said water present in said acidic aqueous paste is between about 15 w/w % to about 25 w/w % based on the total weight of said acidic aqueous paste.

12. The bone cement precursor system of claim 1, wherein said system further comprises an additive.

13. The bone cement precursor system of claim 12, wherein said additive is selected from the group consisting of a protein, osteoinductive material, osteoconductive material, x-ray opacifying agent, medicament, supporting or strengthening filler material, crystal growth adjuster, viscosity modifier, pore forming agent, radiopaque filler and mixtures thereof.

14. A calcium phosphate composition produced by mixing said acidic aqueous paste and said alkaline non-aqueous paste of claim 1.

15. The calcium phosphate composition of claim 14, wherein said calcium phosphate composition is rapid setting.

16. The calcium phosphate composition of claim 14, wherein said calcium phosphate composition is injectable.

17. A bone cement precursor system comprising:

a first container containing an acidic aqueous paste comprising at least one acidic calcium phosphate mineral, at least one synthetic polymer-based paste stabilizing agent, a pH buffering agent and a humectant, and

a second container containing an alkaline non-aqueous paste comprising tetracalcium phosphate (TTCP), polyethylene glycol (PEG), polysorbate 80, and propylene glycol, wherein said alkaline non-aqueous paste comprises a bimodal mean particle size distribution of the TTCP, wherein the mean particle size of a first set of said at least one TTCP mineral is between about 10 μ

m to about 30 μ

m, and the mean particle size of a second set of the at least one TTCP is between about 25 μ

m to about 60 μ

m.

18. The bone cement precursor system of claim 17, wherein the amount of TTCP in said alkaline non-aqueous paste is between about 10 w/w % to about 80 w/w % based on the total weight of said alkaline non-aqueous paste.

19. The bone cement precursor system of claim 17, wherein the amount of the PEG present in said alkaline non-aqueous paste is between about 1 w/w % to about 5 w/w % based on the total weight of said alkaline non-aqueous paste.

20. The bone cement precursor system of claim 17, wherein the amount of the polysorbate 80 in said alkaline non-aqueous paste is between about 0.5 w/w % to about 2 w/w % based on the total weight of said alkaline non-aqueous paste.

21. The bone cement precursor system of claim 17, wherein the amount of said propylene glycol in said alkaline non-aqueous paste is between about 22 w/w % to about 28 w/w % based on the total weight of said alkaline non-aqueous paste.

22. The bone cement precursor system of claim 17, wherein said system further comprises an additive.

23. The bone cement precursor system of claim 22, wherein said additive is selected from the group consisting of a protein, osteoinductive material, osteoconductive material, x-ray opacifying agent, medicament, supporting or strengthening filler material, crystal growth adjuster, viscosity modifier, pore forming agent, radiopaque filler and mixtures thereof.

24. A calcium phosphate composition produced by mixing said acidic aqueous paste and said alkaline non-aqueous paste of claim 17.

25. The calcium phosphate composition of claim 24, wherein said calcium phosphate composition is rapid setting.

26. The calcium phosphate composition of claim 24, wherein said calcium phosphate composition is injectable.